2024
Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma
Yang Z, Cheung R, Jou J, Lim J, Lim Y, Wong R. Association of Baseline Hepatitis B Virus DNA and On-Treatment Risk of Cirrhosis and Hepatocellular Carcinoma. Gastroenterology Research 2024, 17: 109-115. PMID: 38993547, PMCID: PMC11236339, DOI: 10.14740/gr1735.Peer-Reviewed Original ResearchBaseline HBV DNARisk of hepatocellular carcinomaChronic hepatitis BRisk of cirrhosisNon-cirrhotic chronic hepatitis BHepatitis B virus DNAHBV DNAHepatocellular carcinomaHepatitis B virusCHB patientsPropensity score weightingAntiviral therapyAssociated with higher risk of hepatocellular carcinomaHigh risk of hepatocellular carcinomaNon-cirrhotic CHB patientsCohort of CHB patientsLevels of hepatitis B virusContinuous antiviral therapyHigh HBV DNANon-Asian cohortModerate levelsAssociated with higher riskScore weightingB virus DNACox proportional hazards models
1996
Hepatitis in Used Syringes: The Limits of Sensitivity of Techniques to Detect Hepatitis B Virus (HBV) DNA, Hepatitis C Virus (HCV) RNA, and Antibodies to HBV Core and HCV Antigens
Heimer R, Khoshnood K, Jariwala-Freeman B, Duncan B, Harima Y. Hepatitis in Used Syringes: The Limits of Sensitivity of Techniques to Detect Hepatitis B Virus (HBV) DNA, Hepatitis C Virus (HCV) RNA, and Antibodies to HBV Core and HCV Antigens. The Journal Of Infectious Diseases 1996, 173: 997-1000. PMID: 8603983, DOI: 10.1093/infdis/173.4.997.Peer-Reviewed Original ResearchConceptsHepatitis C virus RNAHepatitis B virus DNAHepatitis virus infectionC virus RNAB virus DNAPolymerase chain reactionVirus infectionVirus DNAHBV core antigenVirus RNANeedle exchange programsHCV antibodiesHCV antigensCore antigenHBV coreUsed syringesPCR testingSyringe useDrug usersHCVHBVChain reactionAntibodiesMean limitSyringes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply